Talactoferrin alfa

Drug Profile

Talactoferrin alfa

Alternative Names: Apolactoferrin; Lactoferrin - Agennix; rhLF; Talactoferrin; TLF - Agennix

Latest Information Update: 05 May 2015

Price : $50

At a glance

  • Originator Agennix
  • Developer Agennix; Agennix AG
  • Class Anti-inflammatories; Antineoplastics; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Renal cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic contact dermatitis; Asthma; Bacterial infections; Diabetic foot ulcer; Dry eyes; Gastritis; Mucositis; Non-small cell lung cancer; Nosocomial infections; Psoriasis; Renal cancer; Sepsis

Most Recent Events

  • 06 Aug 2012 Safety and efficacy data from the FORTIS-M phase III trial (monotherapy, third-line therapy) in Non-small cell lung cancer released by Agennix AG
  • 02 Feb 2012 Suspended - Phase-II/III for Sepsis in Canada (PO)
  • 02 Feb 2012 Suspended - Phase-II/III for Sepsis in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top